145 related articles for article (PubMed ID: 21162758)
1. Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma.
Appetecchia M; Meçule A; Pasimeni G; Iannucci CV; De Carli P; Baldelli R; Barnabei A; Cigliana G; Sperduti I; Gallucci M
J Exp Clin Cancer Res; 2010 Dec; 29(1):166. PubMed ID: 21162758
[TBL] [Abstract][Full Text] [Related]
2. Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma.
Sciarra A; Di Silverio F; Autran AM; Salciccia S; Gentilucci A; Alfarone A; Gentile V
Urol Int; 2009; 82(2):147-51. PubMed ID: 19321999
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer.
Lilleby W; Paus E; Skovlund E; Fosså SD
Prostate; 2001 Feb; 46(2):126-33. PubMed ID: 11170140
[TBL] [Abstract][Full Text] [Related]
4. Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer.
Isshiki S; Akakura K; Komiya A; Suzuki H; Kamiya N; Ito H
J Urol; 2002 Feb; 167(2 Pt 1):512-5. PubMed ID: 11792908
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
Zagars GK; Pollack A; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
[TBL] [Abstract][Full Text] [Related]
6. Prostate adenocarcinoma using Gleason scores correlates with prostate-specific antigen and prostate acid phosphatase measurements.
Shih WJ; Gross K; Mitchell B; Collins J; Wierzbinski B; Magoun S; Ryo UY
J Natl Med Assoc; 1992 Dec; 84(12):1049-50. PubMed ID: 1284282
[TBL] [Abstract][Full Text] [Related]
7. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
8. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state.
Zissimopoulos A; Bantis A; Sountoulides P; Giannakopoulos S; Kalaitzis C; Agelonidou E; Touloupidis S
Hell J Nucl Med; 2009; 12(3):234-7. PubMed ID: 19936334
[TBL] [Abstract][Full Text] [Related]
10. Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A.
Sciarra A; Voria G; Monti S; Mazzone L; Mariotti G; Pozza M; D'Eramo G; Silverio FD
Prostate; 2004 Mar; 58(4):421-8. PubMed ID: 14968443
[TBL] [Abstract][Full Text] [Related]
11. Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia.
Sciarra A; Gentile V; Monti S; Dattilo C; Autran Gomez A; Salciccia S; Pannunzi LP; Toscano V; Di Silverio F
Urol Int; 2008; 80(1):68-73. PubMed ID: 18204237
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls.
Marszalek M; Wachter J; Ponholzer A; Leitha T; Rauchenwald M; Madersbacher S
Eur Urol; 2005 Jul; 48(1):34-9. PubMed ID: 15967249
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine differentiation in prostate cancer.
Cerović SJ; Brajusković GR; Vukotić Maletić VD; Mićić SR
Vojnosanit Pregl; 2004; 61(5):513-8. PubMed ID: 15551804
[TBL] [Abstract][Full Text] [Related]
14. Serum tPSA, cPSA, related density parameters and chromogranin A as predictors of positive margins after radical prostatectomy.
Custovic Z; Kraus O; Tomaskovic I; Tarle M
Anticancer Res; 2007; 27(4C):2817-21. PubMed ID: 17695453
[TBL] [Abstract][Full Text] [Related]
15. Low-serum testosterone and high-chromogranin A rare case associated with high-grade prostate cancer and higher pathological stages of the disease.
Izzo L; Cardi A; Pugliese F; Izzo S; Izzo P; Valabrega S; Messineo D; Pieretti G
Ann Ital Chir; 2019; 90():451-456. PubMed ID: 31203267
[TBL] [Abstract][Full Text] [Related]
16. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
Ko EC; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
[TBL] [Abstract][Full Text] [Related]
17. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy.
Alessandro S; Vincenzo G; Maria AG; Stefano S; Alessandro G; Salvatore M; Vincenzo T; Franco DS
Endocr Relat Cancer; 2007 Sep; 14(3):625-32. PubMed ID: 17914093
[TBL] [Abstract][Full Text] [Related]
18. [Total PSA, PSA density and biopsy Gleason score in predicting the pathologic stage of prostate cancer].
Liu S; Lü JJ; Fu Q; Zhang H; Gao DX; Liu Z
Zhonghua Nan Ke Xue; 2010 May; 16(5):415-9. PubMed ID: 20684321
[TBL] [Abstract][Full Text] [Related]
19. Soluble syndecan-1 (SDC1) serum level as an independent pre-operative predictor of cancer-specific survival in prostate cancer.
Szarvas T; Reis H; Vom Dorp F; Tschirdewahn S; Niedworok C; Nyirady P; Schmid KW; Rübben H; Kovalszky I
Prostate; 2016 Aug; 76(11):977-85. PubMed ID: 27062540
[TBL] [Abstract][Full Text] [Related]
20. Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?
Choo R; Hruby G; Hong J; Hong E; DeBoer G; Danjoux C; Morton G; Klotz L; Bhak E; Flavin A
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):674-80. PubMed ID: 11849789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]